Sa1N Syngeneic Model Overview
The Sa1N syngeneic model is a murine fibrosarcoma system derived from A/J mice and represents a well-characterized, immunogenic tumor model frequently used in cancer immunotherapy research. This model was originally established from a spontaneous fibrosarcoma and is noted for its reproducible growth, moderate aggressiveness, and strong responsiveness to immune modulation. Sa1N tumors exhibit features typical of soft tissue sarcomas, including spindle-shaped cell morphology, stromal organization, and localized invasiveness.
When implanted subcutaneously or intramuscularly into immunocompetent A/J mice, Sa1N cells form solid, moderately vascularized tumors with consistent kinetics. The model’s well-balanced immunogenicity and reproducibility make it valuable for studies investigating immune checkpoint inhibitors, cytokine therapies, macrophage activation, and combination immunotherapy strategies aimed at reversing immune suppression in solid tumors.
Request a Custom Quote for Sa1N Syngeneic ModelBiological and Molecular Characteristics
The Sa1N cell line was derived from a spontaneous fibrosarcoma in an A/J mouse and has been widely used to study tumor–immune system interactions. The cells display fibroblast-like morphology and express vimentin and alpha-smooth muscle actin (α-SMA), consistent with mesenchymal lineage. Sa1N tumors secrete pro-inflammatory and immunomodulatory cytokines, including IL-6, TGF-beta, and TNF-alpha, which shape a microenvironment characterized by macrophage infiltration and limited cytotoxic T-cell activity.
This model demonstrates intermediate immunogenicity and predictable tumor progression, allowing researchers to assess both immune stimulation and suppression. Its immune microenvironment includes macrophages, dendritic cells, and T lymphocytes, creating a system suitable for studying cytokine therapy, macrophage polarization, and immune checkpoint regulation. Because of these properties, Sa1N remains one of the standard fibrosarcoma models for preclinical immuno-oncology investigations.
| Parameter | Description |
|---|---|
| Host strain | A/J (female, 6–8 weeks) |
| Tumor origin | Spontaneous fibrosarcoma (mouse) |
| Histological type | Fibrosarcoma |
| Inoculation route | Subcutaneous or intramuscular |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–6 days in vivo |
| Metastatic potential | Low; locally invasive |
| Immunophenotype | Moderately immunogenic; macrophage and T-cell infiltration |
| Common applications | Immunotherapy, cytokine modulation, macrophage activation, vaccine evaluation |
In Vivo Model Development and Tumorigenicity
Sa1N tumors are established through subcutaneous or intramuscular implantation of viable tumor cells into A/J mice. Subcutaneous inoculation produces easily measurable, solid tumors within 5–7 days, while intramuscular implantation generates more stromal-rich lesions useful for studying tumor–matrix interactions. The model’s moderate growth rate and reproducible kinetics make it well-suited for longitudinal analysis of immune responses and therapy-induced changes within the tumor microenvironment.
Because of its moderate immunogenicity, the Sa1N model enables testing of a wide range of immunotherapies, from checkpoint blockade to cytokine-based strategies. Its predictable tumor take rate and intermediate aggressiveness allow precise assessment of therapeutic efficacy, immune infiltration, and resistance mechanisms under controlled experimental conditions.
Request a Custom Quote for Sa1N Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of Sa1N tumors reveals spindle-shaped mesenchymal cells arranged in interwoven fascicles within a collagen-rich stroma. The tumors exhibit moderate vascularization, limited necrosis, and scattered immune infiltrates. Stromal fibroblasts and inflammatory cells form a dense peritumoral capsule that supports local invasion but restricts distant metastasis.
Immunohistochemical staining confirms strong vimentin and α-SMA expression, verifying mesenchymal origin. Ki-67 staining demonstrates active proliferation, while CD31 highlights a moderate vascular network. CD3 and CD8 staining identify T-cell infiltration primarily at the tumor margins, and F4/80 staining confirms macrophage accumulation throughout the stroma. PD-L1 expression is moderate and inducible, consistent with the immune-interactive nature of the Sa1N model. These histological and immunological features mirror those of human soft tissue sarcomas and make Sa1N a relevant system for studying immune regulation and therapeutic response.
Preclinical Applications and Drug Response
The Sa1N syngeneic model is widely used for preclinical evaluation of immunotherapies, cytokine agonists, and macrophage-targeted agents. It demonstrates measurable responsiveness to immune checkpoint inhibitors, including PD-1 and CTLA-4 blockade, especially when combined with cytokine therapies or oncolytic viral vectors. Sa1N tumors have also been used to study radiation-induced immune activation, macrophage polarization, and tumor regression following adoptive T-cell transfer.
Because Sa1N maintains a balance between immune recognition and immune suppression, it serves as an effective model for investigating how immune responses can be enhanced through combination therapies. The model’s controlled growth, defined immune microenvironment, and reproducibility make it a preferred choice for studying immunotherapy mechanisms and evaluating new therapeutic candidates targeting solid fibrosarcomas.
Request This Model
To request the Sa1N syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for Sa1N Syngeneic Model